Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has disclosed Leases for 6 consecutive years, with $51.7 million as the latest value for Q1 2026.

  • Quarterly Leases rose 95.96% to $51.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $51.7 million through Feb 2026, up 95.96% year-over-year, with the annual reading at $50.5 million for FY2025, 79.53% up from the prior year.
  • Leases for Q1 2026 was $51.7 million at Nurix Therapeutics, up from $50.5 million in the prior quarter.
  • The five-year high for Leases was $53.0 million in Q3 2025, with the low at $5.8 million in Q2 2025.
  • Average Leases over 5 years is $24.7 million, with a median of $26.4 million recorded in 2025.
  • The sharpest move saw Leases surged 200.02% in 2024, then crashed 79.89% in 2025.
  • Over 5 years, Leases stood at $12.3 million in 2022, then soared by 152.26% to $31.1 million in 2023, then dropped by 9.64% to $28.1 million in 2024, then surged by 79.53% to $50.5 million in 2025, then grew by 2.26% to $51.7 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $51.7 million, $50.5 million, and $53.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.